NEPH
Nephros, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$4.06
−2.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.7M | 18.8M | 14.2M | 14.2M | 10.0M |
| Cost of Revenue | 8.2M | 7.3M | 5.4M | 5.8M | 5.2M |
| Gross Profit | 12.5M | 11.5M | 8.7M | 8.4M | 4.7M |
| Operating Expenses | |||||
| R&D Expense | 1.4M | 1.3M | 906.0K | 873.0K | 1.3M |
| SG&A Expense | 9.5M | 9.0M | 7.7M | 8.9M | 7.6M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (74.0K) | — | 135.0K | 214.0K | 218.0K |
| Total Operating Expenses | 10.9M | 10.3M | 8.7M | 10.0M | 9.1M |
| Cost and Expenses | 19.1M | 17.6M | 14.2M | 15.8M | 14.3M |
| Operating Income (EBIT) | 1.6M | 1.1M | 6.0K | (1.6M) | (4.3M) |
| Non-Operating | |||||
| Interest Income | 157.0K | 139.0K | 94.0K | 64.0K | 14.0K |
| Interest Expense | 1.0K | 1.0K | 1.0K | 2.0K | 20.0K |
| Net Interest Income | 156.0K | 138.0K | 93.0K | 62.0K | (6.0K) |
| Other Non-Op Income/Expense | 110.0K | 60.0K | 83.0K | 18.0K | 58.0K |
| Non-Operating Income (excl Interest) | (52.0K) | (61.0K) | (84.0K) | (20.0K) | (78.0K) |
| EBT (Pre-Tax Income) | 1.8M | 1.2M | 89.0K | (1.6M) | (4.3M) |
| Income Tax Expense | 16.0K | 12.0K | 15.0K | — | — |
| Bottom Line | |||||
| Net Income | 1.7M | 1.2M | 74.0K | (1.6M) | (7.4M) |
| Earnings from Cont. Ops | 1.7M | 1.2M | 74.0K | (1.6M) | (4.3M) |
| Earnings from Discont. Ops | — | — | — | — | (2.8M) |
| Bottom Line Net Income | 1.7M | 1.2M | 74.0K | (1.6M) | (7.4M) |
| Per Share | |||||
| Basic EPS | $0.16 | $0.11 | $0.01 | ($0.15) | ($0.72) |
| Diluted EPS | $0.16 | $0.11 | $0.01 | ($0.15) | ($0.72) |
| Revenue Per Share | $1.91 | $1.77 | $1.35 | $1.37 | $0.97 |
| Shares | |||||
| Basic Shares Outstanding | 10.9M | 10.6M | 10.5M | 10.4M | 10.3M |
| Diluted Shares Outstanding | 11.1M | 11.0M | 10.6M | 10.4M | 10.3M |
| Profitability Metrics | |||||
| EBITDA | 1.8M | 1.3M | 227.0K | (1.4M) | (3.7M) |
| D&A | 123.0K | 140.0K | 137.0K | 214.0K | 571.0K |
| EBIT | 1.7M | 1.2M | 90.0K | (1.6M) | (4.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026